You just read:

Gastroenterologists Are Gearing Up to Incorporate Novel Oral Agents, Such As Pfizer's Xeljanz, into the Treatment Paradigm for Ulcerative Colitis, According to Latest Data from Spherix Global Insights

News provided by

Spherix Global Insights

Mar 23, 2018, 04:00 ET